<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118295</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0842</org_study_id>
    <nct_id>NCT05118295</nct_id>
  </id_info>
  <brief_title>Single Step Lesion Annotation and Localization of Suspicious Breast Lesions</brief_title>
  <official_title>Single Step Lesion Annotation and Localization of Suspicious Breast Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SAVI Reflector is a nonradioactive infrared (IR)-activated electromagnetic wave device&#xD;
      that can be implanted in the breast or lymph nodes under image-directed guidance, typically&#xD;
      by mammography or sonography. Intraoperatively, the SCOUT hand-held device is then&#xD;
      percutaneously applied to the breast or lymph node, creating an audible signal on the device&#xD;
      console with a gradient which correlates to distance (in mm) from the target lesion and&#xD;
      marker.&#xD;
&#xD;
      The Savi Scout surgical guidance system was approved by the U.S. Food and Drug Administration&#xD;
      in 2014. Furthermore, it was approved for long term use, with no restrictions on the length&#xD;
      of time in 2017.&#xD;
&#xD;
      The system consists of an implantable reflector with a 4-mm body size, preloaded in a&#xD;
      16-gauge deliverable needle, a hand-held probe and a console. The reflector consists of an IR&#xD;
      light receptor, resistor switch and two antennae. This is placed into or near the target&#xD;
      through a 16G needle under mammographic or sonographic guidance. The hand-held probe detects&#xD;
      pulses of infrared (IR) light and radar wave signals, received by the console system, which&#xD;
      then emits and receives signals back to the reflector to provide real time localization and&#xD;
      target proximity information to the surgeon.&#xD;
&#xD;
      The SCOUT console provides audible and visual feedback intraoperatively, the frequency of&#xD;
      which increases as the handheld reader approaches the implanted reflector. After excision of&#xD;
      the breast lesion, the handheld reader can be used to immediately confirm removal of the&#xD;
      reflector, present in the lumpectomy specimen, and subsequent quiescence of radar signal in&#xD;
      the breast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoint:&#xD;
&#xD;
      -To measure success of surgical retrieval of SAVI Scout placed at the time of initial, or&#xD;
      mid-chemo, imaging studies. To demonstrate the successful excision of unifocal tumor tissue&#xD;
      and/or tumor bed (after neoadjuvant chemotherapy).&#xD;
&#xD;
      Other Endpoints:&#xD;
&#xD;
        -  Safety: Number of device-related adverse events.&#xD;
&#xD;
        -  Radiological Placement Radiologist-rated ease of placement using Likert scale&#xD;
&#xD;
        -  Accuracy of placement:&#xD;
&#xD;
        -  Accurate: Within the breast tumor&#xD;
&#xD;
        -  Marginal: Within the peritumoral tissue &lt; or equal 5 mm&#xD;
&#xD;
        -  Inadequate: More than 5 mm&#xD;
&#xD;
        -  Unacceptable: Required additional localization device placement&#xD;
&#xD;
        -  Success rate of maintained position of SAVI Scout, measured on interval imaging:&#xD;
&#xD;
        -  Accurate: Within the breast tumor&#xD;
&#xD;
        -  Marginal: Within the peritumoral tissue &lt; or equal 5 mm&#xD;
&#xD;
        -  Inadequate: More than 5 mm&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2022</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Change From Baseline in Pain Scores on the Visual Analog Scale at 6 Weeks</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Lesions</condition>
  <arm_group>
    <arm_group_label>SAVI Scout®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>marker is accurately placed in the breast tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAVI Scout®</intervention_name>
    <description>Savi Scout marker is placed within 1 cm of the breast tumor</description>
    <arm_group_label>SAVI Scout®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female or male patients &gt;18 years of age at the time of consent.&#xD;
&#xD;
          2. Unifocal BIRADS-5 or -6 lesions at the time of diagnostic imaging&#xD;
&#xD;
          3. Unifocal, histologically-proven T0-T3, N0-1 invasive breast cancer at the time of&#xD;
             mid-chemotherapy imaging if receiving neoadjuvant therapy&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Distant metastasis&#xD;
&#xD;
          2. Inflammatory breast carcinoma&#xD;
&#xD;
          3. Nickel allergy&#xD;
&#xD;
          4. Patients with active cardiac implants&#xD;
&#xD;
          5. Patients participating in Protocol 2016-0046, Multicenter Trial for Eliminating Breast&#xD;
             Cancer Surgery in Exceptional Responders to Neoadjuvant Therapy&#xD;
&#xD;
          6. Patients participating in Protocol AFT-25, Comparison of Operative to Monitoring and&#xD;
             Endocrine Therapy for Low-risk DCIS (COMET)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Moseley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanya Moseley, MD</last_name>
    <phone>(713) 792-5755</phone>
    <email>tstephens@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tanya Moseley</last_name>
      <phone>713-792-5755</phone>
    </contact>
    <contact_backup>
      <last_name>tstephens@mdanderson.org</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

